Financial Performance - The group's revenue increased by approximately 2.5% from about HKD 70.2 million for the year ended March 31, 2021, to about HKD 72 million for the year ended March 31, 2022, primarily due to increased sales of medical gloves and biopsy needles [12]. - Gross profit rose by approximately HKD 2.7 million or 8.1% from about HKD 33.6 million for the year ended March 31, 2021, to about HKD 36.3 million for the year ended March 31, 2022, with the gross profit margin increasing from approximately 47.9% to about 50.5% [13]. - The group's profit decreased from approximately HKD 7,900,000 for the year ended March 31, 2021, to approximately HKD 4,000,000 for the year ended March 31, 2022, mainly due to increased employee costs and a one-time government subsidy in the previous year [18]. - The income tax expense for the year ended March 31, 2022, was approximately HKD 1.4 million, compared to about HKD 1.5 million in 2021 [15]. - The board declared an interim dividend of HKD 0.3 per share for the year ended March 31, 2022, down from HKD 0.45 per share in 2021 [19]. Operational Challenges and Strategies - The group continues to face challenges due to the significant impact of COVID-19 on the economy and customer spending plans [11]. - The group remains optimistic about the healthcare sector due to the growing elderly population and increasing medical awareness among Hong Kong citizens [8]. - The group is actively seeking suitable investment opportunities to diversify its business and enhance returns for shareholders [8]. - The group is focused on leveraging its strengths to diversify its product offerings and expand its customer base [8]. - The group plans to further expand its product portfolio and strengthen customer service to enhance its one-stop medical instrument solution services [11]. Human Resources and Employee Costs - Administrative and other operating expenses increased by approximately HKD 3.8 million or 15.2% from about HKD 25.4 million for the year ended March 31, 2021, to about HKD 29.2 million for the year ended March 31, 2022, mainly due to an increase in the number of employees [14]. - The group employed a total of 41 staff as of March 31, 2022, with employee costs amounting to approximately HKD 18,200,000, an increase from approximately HKD 15,600,000 in 2021 [34]. - The group is actively seeking strategic acquisition opportunities and has hired additional personnel to enhance product development capabilities [39]. Assets and Liabilities - As of March 31, 2022, current assets were approximately HKD 97,400,000, a decrease from approximately HKD 101,800,000 in 2021, while current liabilities decreased to approximately HKD 14,700,000 from HKD 17,500,000 [20]. - The group's cash and bank balances totaled approximately HKD 55,300,000 as of March 31, 2022, down from approximately HKD 70,200,000 in 2021 [21]. - Trade receivables increased to approximately HKD 17,300,000 as of March 31, 2022, compared to approximately HKD 7,700,000 in 2021 [22]. - The group had no significant debt financing, resulting in a debt-to-asset ratio of zero as of March 31, 2022 [23]. Corporate Governance - The company has adopted a new corporate governance code to enhance transparency and accountability, effective from January 1, 2022 [68]. - All directors confirmed compliance with trading standards and ethical guidelines, ensuring no violations occurred during the reporting period [70]. - The board consists of six directors responsible for overall business development goals and long-term company strategy [72]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2022 [75]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, to enhance governance [85]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to sustainable development, integrating environmental, social, and governance (ESG) principles into its business strategy to ensure long-term prosperity [146]. - The board of directors evaluates the potential impact of ESG issues on the overall strategy and monitors the company's performance in these areas [148]. - The company has established goals related to significant ESG issues and actively implements measures to enhance its performance in these areas [149]. - The group has established a working group to enhance employee awareness of environmental, social, and governance (ESG) issues, comprising senior management and staff from various departments [151]. - The ESG report focuses on the operations as a medical device distributor, which is the primary source of revenue for the group, and has expanded its reporting scope due to business growth [152]. Emissions and Resource Management - Direct greenhouse gas emissions (Scope 1) were 21 tons of CO2 equivalent, a decrease from 23 tons in the previous fiscal year [178]. - Total greenhouse gas emissions increased to approximately 53 tons of CO2 equivalent, up about 18% from 45 tons in the previous fiscal year [178]. - The total amount of non-hazardous waste generated was approximately 854 kilograms, an increase of about 15% from 740 kilograms in the previous fiscal year [183]. - The company has set a target to maintain or reduce non-hazardous waste density to approximately 11.86 kilograms per million revenue by the fiscal year 2030 [183]. - The company has implemented various energy and resource-saving measures to achieve its emission reduction goals [172].

Financial Performance - For the three months ended December 31, 2021, the company reported revenue of HKD 20,344,000, an increase of 35% compared to HKD 15,100,000 for the same period in 2020[8] - The gross profit for the three months ended December 31, 2021, was HKD 10,036,000, representing a gross margin of 49.3%, up from HKD 8,159,000 in the same period last year[8] - The net profit attributable to the owners of the company for the three months ended December 31, 2021, was HKD 2,108,000, an increase of 3.6% from HKD 2,035,000 in the previous year[8] - For the nine months ended December 31, 2021, total revenue reached HKD 51,699,000, a 24% increase from HKD 41,244,000 in the same period of 2020[8] - The company’s total comprehensive income for the nine months ended December 31, 2021, was HKD 5,159,000, compared to HKD 4,905,000 for the same period in 2020[8] - The group reported a revenue of HKD 51,699,000 for the nine months ended December 31, 2021, compared to HKD 45,745,000 for the same period in 2020, representing an increase of approximately 12.7%[29] - Revenue from medical consumables was HKD 36,653,000 for the nine months ended December 31, 2021, slightly up from HKD 36,365,000 in the same period of 2020[29] - Revenue from medical equipment surged to HKD 11,832,000 for the nine months ended December 31, 2021, compared to HKD 6,046,000 in the same period of 2020, marking a significant increase of approximately 95.5%[29] - The group’s pre-tax profit for the nine months ended December 31, 2021, was impacted by an increase in employee costs, which rose to HKD 12,052,000 from HKD 10,198,000 in the same period of 2020[36] - The company's profit attributable to shareholders for the nine months ended December 31, 2021, decreased to approximately HKD 5,200,000 from HKD 7,700,000 for the same period in 2020, a reduction of about 32.5%[58] - Revenue increased by approximately 13.0% to about HKD 51,700,000 for the nine months ended December 31, 2021, compared to approximately HKD 45,700,000 for the same period in 2020, primarily due to increased sales of medical equipment[51] - Gross profit for the nine months ended December 31, 2021, was approximately HKD 27,200,000, an increase of about HKD 2,000,000 or 8.2% from HKD 25,200,000 for the same period in 2020[52] - The gross profit margin decreased from approximately 55.0% for the nine months ended December 31, 2020, to about 52.7% for the same period in 2021, mainly due to an increase in sales of lower-margin medical equipment[52] Expenses and Costs - Administrative and other operating expenses for the three months ended December 31, 2021, were HKD 6,751,000, an increase from HKD 5,461,000 in the same period last year[8] - Administrative and other operating expenses increased by approximately 15.0% to about HKD 19,600,000 for the nine months ended December 31, 2021, from approximately HKD 17,000,000 for the same period in 2020, primarily due to an increase in the workforce[53] - The group’s finance costs for the nine months ended December 31, 2021, included interest on lease liabilities of HKD 106,000, up from HKD 70,000 in the same period of 2020[31] - Income tax expense for the nine months ended December 31, 2021, was approximately HKD 1,300,000, compared to HKD 1,600,000 for the same period in 2020[54] Dividends and Shareholder Returns - The group did not declare an interim dividend for the nine months ended December 31, 2021, compared to HKD 3,500,000 declared for the same period in 2020[40] - The company decided not to declare an interim dividend for the nine months ended December 31, 2021, consistent with the previous year[59] Market and Business Strategy - The company continues to focus on its core business of supplying medical instruments and providing related solutions[14] - The company remains optimistic about the healthcare sector's prospects due to increasing demand for resources and solutions, an aging population, and rising healthcare awareness among the public[48] - The company plans to further diversify its product offerings and enhance customer service to improve its one-stop medical equipment solution services[48] - The company is actively seeking suitable investment opportunities to diversify its business and provide better returns to shareholders[48] - The group plans to continue focusing on expanding its market presence in Hong Kong, where all revenues are currently generated, and has no separate segment analysis due to its operational structure[24] Governance and Compliance - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards and have not been audited[20] - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2021, confirming compliance with applicable accounting standards and GEM listing rules[86] - The company has maintained compliance with all corporate governance code provisions, except for the separation of the roles of chairman and CEO[81] - The company’s board of directors has confirmed adherence to trading standards and relevant codes of conduct as of December 31, 2021[78] - The company has established independent checks to ensure the effectiveness and independence of the board despite the CEO also serving as chairman[84] - The company has a diverse board with members possessing various professional backgrounds and expertise, ensuring robust governance[84] Share Options and Securities - The company has adopted a share option scheme to incentivize selected participants, with a total of 21,460,000 options available for exercise as of December 31, 2021[74] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending December 31, 2021[77] - The company has not granted, exercised, or forfeited any share options during the nine months ending December 31, 2021[74] - As of December 31, 2021, B&A Success holds 557,424,000 shares, representing a 69.68% equity stake in the company[69] Research and Development - Research and development expenses amounted to approximately HKD 1,150,000 for the nine months ended December 31, 2021, compared to HKD 363,000 for the same period in 2020, indicating a substantial increase in investment in R&D[36] Customer Contributions - The group had a significant customer contributing HKD 6,498,000, accounting for over 10% of total revenue for the nine months ended December 31, 2021, compared to HKD 5,459,000 from a similar customer in the same period of 2020[26] No New Developments - The company has not announced any new products or technologies during this reporting period[8] - There are no significant market expansions or acquisitions reported in the current financial results[8]

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於同曼群島註冊成立的有限公司) 股份代號：8372 香港聯合交易所有限公司(「香港聯交所」) GEM 的特色 GEM 的定位乃為相比超其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險,並應經過 審償周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然,在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告(君百延集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我 們」} 各 董事(「董事」) 願就此共同及個別承擔全部責任）乃遵照香港聯交所 GEM 證券 上市規則(「GEM上市規則」 ...

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於同曼群島註冊成立的有限公司) 股份代號：8372 第 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市規則」）提供有關本 ...

Financial Performance - The group's revenue increased by approximately 4.5% from about HKD 67.2 million for the year ended March 31, 2020, to about HKD 70.2 million for the year ended March 31, 2021, primarily due to strong sales of the pharmacy automation system[13]. - Gross profit decreased by approximately HKD 2.8 million or 7.6% from about HKD 36.4 million for the year ended March 31, 2020, to about HKD 33.6 million for the year ended March 31, 2021, with the gross profit margin dropping from approximately 54.1% to 47.9%[14]. - Net profit decreased by approximately HKD 1.7 million from about HKD 9.6 million for the year ended March 31, 2020, to about HKD 7.9 million for the year ended March 31, 2021, mainly due to the reduction in gross profit[18]. - Administrative and other operating expenses increased by approximately HKD 1 million or 4.0% from about HKD 24.4 million for the year ended March 31, 2020, to about HKD 25.4 million for the year ended March 31, 2021, primarily due to an increase in the number of employees[15]. - The income tax expense for the year ended March 31, 2021, was approximately HKD 1.5 million, down from HKD 2.3 million in 2020[16]. - The total cash and bank balances as of March 31, 2021, were approximately HKD 70.2 million, slightly down from HKD 70.6 million in 2020[21]. - The group had no significant capital commitments or major investments as of March 31, 2021, maintaining a debt-free status with a debt-to-asset ratio of zero[22][29]. - Employee costs for the year ended March 31, 2021, were approximately HKD 15.6 million, up from HKD 14 million in 2020, with a total of 34 employees compared to 33 in the previous year[33]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.45 per ordinary share for the year ended March 31, 2021, compared to HKD 0.4375 per share for 2020[19]. - The dividend policy considers factors such as actual and expected financial performance, capital and debt levels, and operational funding needs[132]. - Dividends may be paid in cash or through the issuance of shares, subject to legal and regulatory compliance[134]. - The board has the discretion to decide on dividend payments based on various factors, including capital structure and future opportunities[137]. - The dividend policy is published on the company's website for investor reference[139]. Market and Product Development - The company successfully supplied Hong Kong's first pharmacy automation system, enhancing its position as a pioneer in this technology[9]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing healthcare awareness among Hong Kong citizens[9]. - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[12]. - The company aims to address the healthcare workforce shortage in Hong Kong through its automation solutions[9]. - The actual net proceeds from the share offering were approximately HKD 31.2 million, with a difference of HKD 1.9 million from the estimated proceeds of HKD 33.1 million disclosed in the prospectus[37]. - The group plans to utilize HKD 6.1 million for further penetration into the medical device market, with HKD 5.5 million remaining to be used by March 31, 2022[39]. - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge[44][52]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on enhancing user experience and engagement[75]. - Market expansion efforts include entering two new regions, which are anticipated to increase market share by 5%[75]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a budget of up to HKD 300 million allocated for potential deals[75]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance and compliance through its various committees[44][50]. - The board consists of six members, including the Chairperson and CEO, ensuring a balanced composition in terms of age, gender, and tenure[64]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2021[65]. - The attendance record for board meetings shows that all directors participated actively, with most attending 100% of the meetings[68]. - The company has a strong focus on risk management and internal controls, delegating daily operations and business development plans to the management team[71]. - The management team is required to obtain board approval before entering into any significant transactions or contracts[71]. - The company has maintained a high level of corporate governance, which is crucial for enhancing corporate value and accountability[60]. - The board includes independent non-executive directors, with at least one possessing appropriate professional qualifications in accounting or related financial management[71]. - The company emphasizes transparency and shareholder rights as part of its governance practices[60]. - The management team has over 20 years of experience in accounting, auditing, and financial management, contributing to the company's strategic direction[58]. - The company has established a robust investor relations strategy to communicate effectively with stakeholders[48]. - The company has established measurable goals for board member diversity and monitors progress towards achieving these goals[102]. Environmental, Social, and Governance (ESG) Initiatives - The report emphasizes the importance of integrating environmental, social, and governance (ESG) principles into the company's risk management system[141]. - The ESG report covers activities, challenges, and measures taken during the fiscal year ending March 31, 2021[146]. - Stakeholder engagement is prioritized, with communication channels established for feedback from shareholders, customers, suppliers, and regulatory bodies[148]. - Key performance indicators related to ESG are collected and reported, focusing on direct operational control within the company and its subsidiaries[143]. - The company is committed to continuous assessment and improvement of its ESG risk management and internal control systems[155]. - The report identifies significant ESG issues, including product safety, employee welfare, and regulatory compliance[155]. - The company has established a whistleblowing mechanism for stakeholders to report suspected misconduct or policy violations[158]. - The ESG report is prepared in accordance with the guidelines set forth by the Hong Kong Stock Exchange[144]. - The company aims to create greater value for the community through collaboration with stakeholders and addressing their expectations[148]. - The total greenhouse gas emissions decreased from approximately 55 tons of CO2 equivalent in FY2020 to about 45 tons in FY2021, representing a reduction of approximately 18.2%[167]. - The total paper consumption decreased from approximately 836 kg in FY2020 to about 740 kg in FY2021, a reduction of approximately 11.5%[175]. - The company has implemented various energy-saving measures to achieve its emission reduction and energy efficiency goals[162]. - The company has not reported any significant violations of environmental laws and regulations during the reporting period[167]. - Energy consumption decreased from approximately 146,139 kWh in FY2020 to about 132,563 kWh in FY2021, representing a reduction of approximately 9.3%[181]. - Total water consumption reduced from approximately 8 cubic meters in FY2020 to 3 cubic meters in FY2021, a decrease of about 62.5%[184]. - The company encourages employees to participate in activities promoting a green environment, enhancing awareness of energy management[181]. - The company has established policies to ensure fair treatment and equal opportunities for all employees, with a zero-tolerance approach to workplace harassment[199].

Financial Performance - For the nine months ended December 31, 2020, the group's revenue was HKD 45,745,000, a decrease of 8.1% compared to HKD 49,249,000 for the same period in 2019[7]. - Gross profit for the nine months was HKD 25,169,000, representing a slight decrease of 2.1% from HKD 25,711,000 in the previous year[7]. - The net profit attributable to the owners of the company for the nine months was HKD 7,729,000, down 2.3% from HKD 7,914,000 in the same period last year[7]. - Basic earnings per share for the nine months was HKD 0.97, compared to HKD 0.99 for the same period in 2019[7]. - Total comprehensive income for the three months ended December 31, 2020, was HKD 2,035,000, down from HKD 3,331,000 in the same period of 2019, a decrease of 38.9%[7]. - The group reported a profit attributable to owners of the company of HKD 7,729,000 for the nine months ended December 31, 2020, a decrease from HKD 7,914,000 in the previous year[47]. - The company recorded a profit of approximately HKD 7,700,000 for the nine months ended December 31, 2020, down from HKD 7,900,000 in the same period of 2019[65]. Revenue and Expenses - The group incurred administrative and other operating expenses of HKD 17,038,000 for the nine months, an increase of 8.1% from HKD 15,754,000 in the previous year[7]. - Financial costs for the nine months were HKD 70,000, down from HKD 149,000 in the previous year, a decrease of 53.0%[7]. - The group incurred research and development expenses of approximately HKD 363,000 for the nine months ended December 31, 2020, compared to HKD 432,000 in the same period of 2019[36]. - Administrative and other operating expenses increased by approximately HKD 1,200,000 or 8.2% to about HKD 17,000,000 for the nine months ended December 31, 2020, primarily due to an increase in the workforce[59]. Revenue Trends - The group reported a revenue of HKD 15,100,000 for the three months ended December 31, 2020, a decrease of 12.5% compared to HKD 17,248,000 in the same period of 2019[26]. - For the nine months ended December 31, 2020, the revenue was HKD 45,745,000, down 7.6% from HKD 49,249,000 in the previous year[26]. - Revenue from a major customer amounted to HKD 5,459,000, representing over 10% of the group's total revenue for the nine months ended December 31, 2020[27]. - The company's revenue decreased by approximately 7.1% from about HKD 49,200,000 in the nine months ended December 31, 2019, to about HKD 45,700,000 in the nine months ended December 31, 2020[57]. Dividends and Shareholder Information - The group did not declare an interim dividend for the nine months ended December 31, 2020, consistent with the previous year[41]. - The company did not declare an interim dividend for the nine months ended December 31, 2020[66]. - As of December 31, 2020, B&A Success holds 557,424,000 shares, representing 69.68% of the company's total equity[77]. - The company has a stock option plan that allows for the issuance of up to 80,000,000 shares, which is 10% of the total shares issued at the time of listing[78]. - At the end of the reporting period, a total of 71,940,000 shares are available for issuance under the stock option plan, accounting for 8.99% of the company's total issued share capital[81]. - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the nine months ending December 31, 2020[87]. Market and Strategic Outlook - The company has not announced any new products or technologies during this reporting period[14]. - There are no significant market expansion or acquisition strategies mentioned in the report[14]. - The company is supplying Hong Kong's first pharmacy automation system, which is expected to address healthcare labor shortages and instill confidence in potential clients[54]. - The company plans to further expand its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[54]. - The economic impact of COVID-19 has significantly affected customer spending plans, leading to challenges for the company's clients[54]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing medical awareness among Hong Kong citizens[54]. - The company continues to monitor the developments of COVID-19 and its potential impact on financial performance[51]. Compliance and Audit - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2020, and confirmed compliance with applicable accounting standards and GEM listing rules[96]. - The group’s total non-current assets are primarily located in Hong Kong, with all revenue generated from this region[24]. - The group has only one operating segment as per the Hong Kong Financial Reporting Standards, focusing on the supply of medical instruments and related solutions[23]. - The group’s interest expenses on lease liabilities were HKD 70,000 for the nine months ended December 31, 2020, down from HKD 149,000 in the previous year[33]. - The group’s bank interest income decreased to HKD (346,000) for the nine months ended December 31, 2020, compared to HKD (693,000) in the same period of 2019[36]. - Gross profit for the nine months ended December 31, 2020, was approximately HKD 25,200,000, compared to HKD 25,700,000 for the same period in 2019, with the gross profit margin increasing from 52.2% to 55.0%[58].

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號：8372 BOODORDOOD 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市 ...

Financial Performance - For the three months ended June 30, 2020, the company reported revenue of HKD 14,010,000, a decrease of 3.2% from HKD 14,471,000 in the same period of 2019[7] - Gross profit for the same period was HKD 8,200,000, representing an increase of 6.2% compared to HKD 7,719,000 in 2019[7] - The company recorded a profit before tax of HKD 3,391,000, up 57.0% from HKD 2,160,000 in the previous year[7] - Net profit attributable to owners of the company was HKD 2,920,000, an increase of 68.8% from HKD 1,731,000 in the same quarter of 2019[7] - Basic and diluted earnings per share for the period were HKD 0.37, compared to HKD 0.22 in the previous year, reflecting a growth of 68.2%[7] - Other income increased significantly to HKD 1,035,000 from HKD 228,000, marking a growth of 353.5% year-on-year[7] - The group reported a tax expense of 471,000 HKD for the three months ended June 30, 2020, compared to 429,000 HKD for the same period in 2019, reflecting an increase of about 9.8%[77] - Profit for the period was approximately HKD 2,900,000 for the three months ended June 30, 2020, compared to HKD 1,700,000 for the same period in 2019, primarily due to increased other income and gross profit[105] Revenue Breakdown - Revenue from medical consumables was 11,748,000 HKD in Q2 2020, up from 10,530,000 HKD in Q2 2019, indicating an increase of approximately 11.5%[69] - The group recognized contract revenue of 13,951,000 HKD for the three months ended June 30, 2020, compared to 14,431,000 HKD in the same period of 2019, reflecting a decline of about 3.3%[69] - The group had a significant customer contributing approximately 2,892,000 HKD, accounting for over 10% of total revenue for the three months ended June 30, 2020, whereas no single customer contributed over 10% in the same period of 2019[66] Expenses and Costs - The company incurred finance costs of HKD 16,000, a decrease of 67.3% from HKD 49,000 in the same period last year[7] - Distribution and selling expenses were HKD 210,000, a decrease from HKD 258,000 in the previous year, indicating a reduction of 18.6%[7] - Administrative and other operating expenses increased by approximately HKD 200,000 or 3.6% to HKD 5,700,000 for the three months ended June 30, 2020, mainly due to increased employee costs[101] - Research and development expenses for the three months ended June 30, 2020, were approximately 112,000 HKD, compared to 132,000 HKD for the same period in 2019[74] Corporate Governance - The company has adhered to all provisions of the corporate governance code, with the exception of the chairman and CEO roles being held by the same individual[165] - The company confirmed that all directors complied with the trading standards and relevant codes of conduct during the reporting period[160] - The audit committee, established on March 1, 2018, reviewed the unaudited condensed consolidated financial statements for the three months ended June 30, 2020, ensuring compliance with applicable accounting standards[169] - The company has established independent checks to ensure the effectiveness and independence of the board despite the dual role of the chairman and CEO[166] Share Options and Equity - As of June 30, 2020, B&A Success holds 557,424,000 shares, representing approximately 69.68% of the company's equity[150] - The company adopted a share option scheme on March 1, 2018, allowing selected participants to be granted options as an incentive for their contributions[153] - As of June 30, 2020, a total of 22,460,000 share options were available, with 21,460,000 remaining after accounting for 1,000,000 options exercised[154] - The exercise price for the share options granted on April 18, 2019, is HKD 0.12 per share[156] - No share options were granted, exercised, forfeited, cancelled, or lapsed during the three months ended June 30, 2020[156] Market and Product Development - The company has not announced any new products or technologies during this reporting period[6] - There are no updates on market expansion or mergers and acquisitions mentioned in the report[6] - The company is the first to supply an automated system for operating rooms in Hong Kong, addressing healthcare labor shortages and enhancing confidence among potential clients[96] - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[96] - The economic impact of COVID-19 significantly affected the number of travelers from mainland China to Hong Kong, posing challenges for client businesses[96] - The company maintains a positive outlook on the healthcare sector due to the growing elderly population and increasing medical awareness among Hong Kong citizens[96] Dividends - The group did not recommend any dividend for the three months ended June 30, 2020, consistent with the same period in 2019[78] - No dividend was declared for the three months ended June 30, 2020, consistent with the previous period[106]

Financial Performance - For the fiscal year ending March 31, 2020, the company's revenue increased by approximately 15.9% to about HKD 67.2 million from approximately HKD 58 million for the previous fiscal year[13]. - Gross profit rose by approximately HKD 5 million or 15.9% to about HKD 36.4 million, maintaining a stable gross margin of approximately 54.1% for 2020 compared to 54.2% for 2019[14]. - The group's profit increased from approximately HKD 6,600,000 for the year ended March 31, 2019, to approximately HKD 9,600,000 for the year ended March 31, 2020, representing an increase of about 45.5%[18]. - Income tax expense for the fiscal year was approximately HKD 2.3 million, up from HKD 1.6 million in the previous year[17]. - The company reported a total revenue of HKD 578,000 for the fiscal year ending March 31, 2020, for audit services provided by its auditor[111]. - Total revenue for FY2020 was approximately HKD 67.2 million, compared to HKD 58 million in FY2019[171]. Operational Strategy - The company plans to expand its product portfolio and enhance customer service to improve its one-stop medical device solution offerings[12]. - The company aims to leverage its strengths to diversify its product offerings and expand its customer base amid challenges from the US-China trade war and COVID-19[9]. - The company has strengthened its operational team resources to ensure timely delivery of products and support business growth[12]. - The company has recruited talent across various business departments to support and sustain business growth[12]. - The company has implemented new operational strategies to improve efficiency, which are expected to reduce costs by G% in the upcoming year[49]. Market Outlook - The company is optimistic about the healthcare sector's prospects, driven by an aging population and increasing medical awareness among Hong Kong citizens[9]. - The company is pioneering the first pharmacy automation system in Hong Kong, which is expected to address healthcare labor shortages[9]. - The company is expanding its market presence in the Greater Bay Area, targeting a D% increase in market share over the next two years[49]. - New product launches are anticipated to contribute an additional C million in revenue, with a focus on innovative technology in the healthcare sector[49]. Governance and Compliance - The company has adopted the corporate governance code as per GEM Listing Rules Appendix 15, ensuring compliance with all provisions except for one specific clause[61]. - The board of directors consists of six members, responsible for overall business development goals and long-term company strategy[65]. - The company emphasizes high standards of corporate governance to enhance corporate value and accountability, protecting shareholder interests[61]. - The company has implemented strict trading standards for directors, ensuring compliance with relevant codes of conduct[62]. - The audit committee held five meetings during the fiscal year ending March 31, 2020, reviewing the annual report, financial statements, and risk management procedures[85]. Risk Management - The company has established a risk management policy to identify, assess, and manage key business risks, with departments responsible for regular risk identification and assessment[113]. - The board confirmed its responsibility for the effectiveness and adequacy of the risk management and internal control systems, conducting quarterly reviews[113]. - The company is closely monitoring foreign exchange risks and may consider hedging measures to mitigate potential impacts on operational performance[32]. - The group has confirmed that its risk management and internal control systems are effective and adequate[114]. Environmental, Social, and Governance (ESG) - The group is committed to sustainable development and has integrated environmental, social, and governance principles into its business strategy[135]. - The group focuses on environmental, social, and governance (ESG) issues, identifying key topics through stakeholder engagement and assessments[154]. - The ESG report covers the fiscal year ending March 31, 2020, detailing activities, challenges, and measures taken in ESG areas[140]. - Total greenhouse gas emissions decreased by approximately 20.3% from about 69 tons of CO2 equivalent in FY2019 to about 55 tons in FY2020[164]. - The group has implemented environmental policies aimed at reducing resource usage and promoting recycling and waste management principles[161]. Employee Welfare - The company has a total of 33 full-time employees as of March 31, 2020[190]. - Employee turnover rate is 83.9% for males and 57.1% for females[193]. - The company has not recorded any work-related fatalities, indicating a work-related death rate of zero[199]. - The company has implemented air purification equipment to ensure good indoor air quality in the workplace[186]. - The company is committed to maintaining a safe and healthy work environment through regular monitoring and training[200].

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號：8372 香港聯合交易所有限公司(「香港聯交所」) GEM 的特色 GEM 的定位乃為相比超其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險,並應經過 審慎周詳考慮後方作出投資決定。GEM 的較高風險及其他特色表示GEM 較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然,在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告(君百延集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我 們」} 各 董 李 (「 董 李 [ 董 李 [ 董 ] ] 」 上市規則([GEM上市規則])提供有關本集團的資料 ...